# Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

> **NCT03862911** · NA · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 330 (estimated)

## Conditions studied

- Metastatic Tumors

## Interventions

- **RADIATION:** palliative radiotherapy
- **RADIATION:** Stereotactic ablative radiotherapy

## Key facts

- **NCT ID:** NCT03862911
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-11-01
- **Primary completion:** 2030-11-24
- **Final completion:** 2030-12-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862911, "Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03862911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*